OUR FUNDING
Use this space to introduce yourself and share your professional history.
Novo Holdings is a founding investor in Acesion Pharma and invested in the company through Novo Seeds, the early stage investment arm of Novo Holdings.
In 2023 Canaan co-led a series B series totaling 45M euros
In 2023 Alpha Wave Global co-led a series B series totaling 45M euros
In 2023 Global Bioaccess Fund joined a series B series totaling 45M euros
UK based Wellcome Trust has provided substantial funding to Acesion Pharma in several rounds, through their Seeding Drug Discovery Initiative (SDDI) and the Translational Award program, to advance Acesion Pharma's development program aiming for an acute treatment of atrial fibrillation (AF).
FC Capital provided early phase funding.
Broadview Ventures provided early stage funding.
Innovation Fund Denmark provided a funding of 5M DKK to Acesion to support the human Proof-of-Concept study in AF through their Innobooster Program.